Medicenna Completes MDNA11 Dose Escalation And Commences Monotherapy Dose Expansion In The Phase 1/2 ABILITY Study
Portfolio Pulse from Happy Mohamed
Medicenna Therapeutics Corp. (NASDAQ:MDNA) has announced a clinical update on the monotherapy dose escalation portion of the Phase 1/2 ABILITY Study for its drug candidate MDNA11. The drug has shown durable single-agent activity in patients with advanced, treatment-refractory cancer, with a manageable safety profile. The company is now initiating the dose expansion phase of the study, with the recommended dose for expansion set at 90g/kg. Initial results from the monotherapy dose expansion are expected in Q4 2023.
August 09, 2023 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicenna's MDNA11 drug has shown promising results in the Phase 1/2 ABILITY Study, potentially boosting investor confidence in the company.
The positive results from the Phase 1/2 ABILITY Study for Medicenna's drug candidate MDNA11 could lead to increased investor confidence in the company's ability to develop effective treatments. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100